Search

Your search keyword '"Pol Stanislas"' showing total 2,116 results

Search Constraints

Start Over You searched for: Author "Pol Stanislas" Remove constraint Author: "Pol Stanislas"
2,116 results on '"Pol Stanislas"'

Search Results

1. Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort

2. Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis

3. Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 study

6. Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide

7. Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort

8. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes

10. Hepatitis D Virus Infection Markedly Increases the Risk of Hepatocellular Carcinoma in Patients with Viral B Cirrhosis

12. Hepatitis C virus-specific cellular immune responses in individuals with no evidence of infection

13. Unknown Circovirus in Immunosuppressed Patient with Hepatitis, France, 2022

14. Hepatic profile analyses of tipranavir in Phase II and III clinical trials

15. Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors

16. Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later?

17. Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort

18. Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis

20. Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease

22. Early IFNβ secretion determines variable downstream IL-12p70 responses upon TLR4 activation

24. Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response

25. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

28. Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus

30. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis

32. Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis

33. Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort

34. Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study

36. Differential levels of IFNα subtypes in autoimmunity and viral infection

38. Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance

39. Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment

40. Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area

41. Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort

42. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death

43. Personalized surveillance for hepatocellular carcinoma in cirrhosis – using machine learning adapted to HCV status

44. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

45. Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D

46. WED-245 Should specific cutoffs be used for diagnosing fibrotic MASH in patients with type 2 diabetes using FAST, MAST, MEFIB and FNI?

47. GS-002 48-week off-therapy efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: final results from the phase 2b, open-label, randomised, multicentre study MYR204

49. FRI-371 Undetectable HDV RNA at 24 weeks of treatment with combination therapy is an important predictor of maintained response off-therapy

50. WED-410 Sustained virological response after treatment with Bulevirtide in HDV patients. Data from the french multicenter real-life cohort

Catalog

Books, media, physical & digital resources